NCT00413413
Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension
See it on ClinicalTrials.gov ↗916 people
37.8%
62.2%
346 womenmiddle line = equal numbers570 men
- Phase
- PHASE3
- Paid for by
- Novartis Pharmaceuticals
- Finished
- 2007-11
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – 85 Years
- Average age
- mean 51.5 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnant or nursing women”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant or nursing women”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Evidence of hepatic disease”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“History of hypertensive encephalopathy, cerebrovascular accident or transient ischemic attack, myocardial infarction or other types of revascularization”
- No diabetes
Women with diabetes were turned away.
“All patients with Type I diabetes and those patients with Type 2 diabetes who are not well controlled based on the investigator's clinical judgment”
- No cancer
Women with current or past cancer were turned away.
“Malignant hypertension”
Study titles and rules are shown in their original English.